Browse the search results

Animal experiments show that the mosaic-type immunogen integrating key mutations from Omicron and other circulating variants elicits broad neutralization against divergent SARS-CoV-2 strains.

The humoral and cellular immune responses were evaluated for two immunization schedules for the inactivated SARS-CoV-2 vaccine, CoronaVac, with two doses separated by 2 or 4 weeks, showing that these responses are mostly similar, with differences in neutralization capacities.

Genomic analysis of initial SARS-CoV-2 waves in Kenya revealed Mombasa City as a key gateway for variants entering Coastal Kenya with onward inter-county transmission highlighting significance of surveillance in major cities for early warning of lineages entering local populations.

A critical role for glycosylation on viral entry and methods to use this knowledge to reduce SARS-CoV-2 infectivity has been demonstrated.

P4-ATPase BbCrpa detoxifies secondary metabolites via a unique vesicle-mediated transport pathway that targets the compounds into vacuoles.

A new class of antibody binding a highly conserved epitope on the spike S2 domain of MERS-CoV, SARS-CoV, and SARS-CoV-2 viruses is described.

Common variants of the SARS-CoV-2 Spike protein and its ligand, the human ACE2 receptor, increase the binding affinity, suggesting that they could increase viral transmissibility.

Intervention of CHI3L1 using anti-CHI3L1 monoclonal antibody or chitinase inhibitor kasugamycin blocks epithelial infection of various SARS-CoV2 variants, suggesting that CHI3L1 is a universal and effective therapeutic target of COVID-19 infection, including recent omicron variants.

COVID-19 CG is an open source web resource that allows vaccine, therapeutics, and diagnostics developers to track SARS-CoV-2 mutations and lineages by location and time.